3.1 Serum IL -18 levels are comparable between diabetic patients and control subjects
The clinical and biochemical features of the subjects included in the study are summarized in Table 1. The levels of FBG, HbA1c and AGEs in type 2 DR were significantly higher than those in control group. However, the levels of serum IL-18 were comparable between type 2 DR patients and control subjects (Table 1). It can be concluded that the IL-18 levels was security treatment in type 2 DR.
3.2 Diabetic retinopathy was related to IL-18 levels
Type 2 diabetes patients were divided into three groups according to diabetic retinopathy lesions: NDR, NPDR, and PDR. As shown in Table 2, the expression level of IL-18 in three groups of type 2 DR were slightly upregulated than that in controls, respectively, but none of them were significantly different. Thus, the level of serum IL-18 was not associated with the severity of type 2 diabete.
3.3 Duration of diabetes were related to IL-18 levels
Type 2 diabetes patients were further divided into four groups according to duration of diabetes: 0-5years,5-10years,10-15years,15 years. As shown in Table 3 the duration of diabetes were not associated with the security of type 2 DR.
3.4The relative expression of IL-18 mRNA
The IL-18 mRNA levels were examined by a realtime quantitative PCR detecting system (qPCR). The IL-18 mRNA level was detected in 4 control subjects and 7 type 2 DR patients. As shown in Fig. 1, the expression of IL-18 was slightly upregulated in diabetes patients but not significantly when compared to control groups (p = 0.07).Type 2 diabetes patients were divided into three groups according to serum IL-18 levels: ≤ 80 pg/ml, 80–120 pg/ml, and > 120 pg/ml. As the increase of IL – 18 levels, the patient's vision had no obvious change. Thus, the serum IL-18 levels were not affected by the vision of patients. From the above results, it can be inferred that IL-18 plays an important role in security treatment that has no side effect.
3.5FBG was related to IL-18 levels
In diabetic patients, we found a significant correlation between the level of serum IL-18 and FBG (r = 0.15, p = 0.03) and then HbA1c (r = 0.15, p = 0.02) was relatively high.
These results suggest that IL-18 expressed in normal human and diabetic patients were within the normal range. Although with diabetic retinopathy level aggravating and serum IL − 18 with increased slightly in type 2 diabetic patients, the difference was not statistically significant. Thus, IL-18 level and type 2 DR were no correlation.
Table 1
Clinical and biochemical features of the subjects
| Control group | Diabetic patients | p |
n = 40 | n = 206 | |
Age(years) | 61.5 ± 5.0 | 57.8 ± 7.9 | 0.861 |
Duration of diabetes (years) | - | 9.4 ± 5.5 | - |
FBG(mmol/L) | 5.6 ± 0.9 | 9.7 ± 2.7 | 0.021 |
HbA1c (%) | 5.2 ± 0.7 | 8.1 ± 1.8 | 0.026 |
AGEs | 0.1 ± 0.04 | 0.3 ± 0.06 | 0.041 |
IL-18 (pg/ml) | 107.4 ± 36.6 | 112.5 ± 32.0 | 0.463 |
Abbreviations: FBG, fasting blood glucose; AGEs, spontaneous fluorescence value; IL-18, interleukin-18. |
Table 2
The serum IL-18 levels of diabetic retinopathy
| Control group | | Diabetic patients | |
| n = 40 | NDR | NPDR | PDR |
n = 69 | n = 52 | N = 85 |
IL-18 (pg/ml) | 107.4 ± 36.6 | 113.0 ± 32.1 | 110.8 ± 31.4 | 114.5 ± 33.4 |
p | | 0.897 | 0.428 | 0.608 |
p values were obtained from t test between diabetic patients and control subjects |
Table 3
The serum IL-18 levels of duration of diabetes
| Control group | | Diabetic patients | (years) | |
| n = 40 | ≦ 5 | 5–10 | 10–15 | 15 |
n = 53 | n = 94 | n = 25 | n = 31 |
IL-18 (pg/ml) | 107.4 ± 36.6 | 113.9 ± 31.3 | 113.6 ± 33.1 | 109 ± 30.7 | 112.7 ± 33.5 |
p | | 0.341 | 0.266 | 0.942 | 0.873 |
p values were obtained from t test between diabetic patients and control subjects |